Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus Ibrance (palbociclib), those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to Faslodex (fulvestrant) plus Ibrance, according to results from the phase III PADA-1 clinical trial.
The REZILIENT3 trial, a global phase III clinical trial evaluating the combination of zipalertinib and platinum-based chemotherapy compared with chemotherapy alone in the first-line treatment of adult patients with previously untreated, locally advanced or metastatic non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations, met its primary endpoint of progression-free survival at a planned interim analysis.
